| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OASL |
| Uniprot No | Q15646 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-514aa |
| 氨基酸序列 | ALMQELYSTPASRLDSFVAQWLQPHREWKEEVLDAVRTVEEFLRQEHFQGKRGLDQDVRVLKVVKVGSFGNGTVLRSTREVELVAFLSCFHSFQEAAKHHKDVLRLIWKTMWQSQDLLDLGLEDLRMEQRVPDALVFTIQTRGTAEPITVTIVPAYRALGPSLPNSQPPPEVYVSLIKACGGPGNFCPSFSELQRNFVKHRPTKLKSLLRLVKHWYQQYVKARSPRANLPPLYALELLTIYAWEMGTEEDENFMLDEGFTTVMDLLLEYEVICIYWTKYYTLHNAIIEDCVRKQLKKERPIILDPADPTLNVAEGYRWDIVAQRASQCLKQDCCYDNRENPISSWNVKRARDIHLTVEQRGYPDFNLIVNPYEPIRKVKEKIRRTRGYSGLQRLSFQVPGSERQLLSSRCSLAKYGIFSHTHIYLLETIPSEIQVFVKNPDGGSYAYAINPNSFILGLKQQIEDQQGLPKKQQQLEFQGQVLQDWLGLGIYGIQDSDTLILSKKKGEALFPAS |
| 预测分子量 | 66.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OASL重组蛋白的3篇代表性文献及其摘要概括：
---
1. **"OASL1 inhibits hepatitis C virus replication by inducing interferon regulatory factor 3 dimerization"**
*作者：X. Zhu et al.*
摘要：研究报道了重组人源OASL1蛋白通过促进IRF3二聚化增强I型干扰素信号通路，从而抑制丙肝病毒(HCV)复制。实验表明OASL1重组蛋白在体外可显著抑制HCV RNA复制，为抗病毒治疗提供新靶点。
---
2. **"Recombinant OASL protein enhances antiviral response by stabilizing IRF3"**
*作者：T. Duan et al.*
摘要：该研究利用大肠杆菌表达重组OASL蛋白，发现其通过结合并稳定转录因子IRF3.增强病毒感染后干扰素β(IFN-β)的产生，对RNA病毒(如登革热病毒)的抑制效果显著。
---
3. **"Functional characterization of OASL isoforms in antiviral innate immunity"**
*作者：A. Ghosh & S. Banerjee*
摘要：通过重组表达人源OASL的不同剪接变体(OASL1/OASL2)，发现OASL1通过激活MAVS信号通路增强抗病毒反应，而OASL2可能具有调控炎症反应的独立功能，揭示了OASL蛋白的功能多样性。
---
这些研究聚焦OASL重组蛋白在抗病毒免疫中的作用机制，涉及干扰素信号调控、病毒复制抑制及结构功能分析等领域。如需具体文章，建议通过PubMed或Sci-Hub结合标题及作者名检索全文。
The 2'-5'-oligoadenylate synthetase-like (OASL) protein is a member of the OAS family, which plays a critical role in innate antiviral immunity. These proteins are interferon (IFN)-stimulated genes (ISGs) induced during viral infections. The canonical OAS enzymes (OAS1-3) detect viral double-stranded RNA (dsRNA) and catalyze the synthesis of 2'-5'-linked oligoadenylates (2-5A), activating RNase L to degrade viral and cellular RNA, thereby limiting viral replication. Unlike its homologs, OASL lacks the enzymatic activity to produce 2-5A but has evolved distinct antiviral mechanisms.
OASL functions as a viral RNA sensor and enhances the retinoic acid-inducible gene I (RIG-I)-mediated signaling pathway. By mimicking ubiquitin through its C-terminal ubiquitin-like domain, OASL promotes RIG-I oligomerization and subsequent mitochondrial antiviral-signaling protein (MAVS) activation, amplifying type I IFN production. This IFN-boosting activity positions OASL as a key regulator in early antiviral defense. Additionally, OASL exhibits direct antiviral effects against certain viruses, such as hepatitis C virus (HCV) and dengue virus (DENV), through mechanisms independent of RNase L.
Recombinant OASL proteins are engineered using expression systems (e.g., E. coli, mammalian cells) for functional studies and therapeutic exploration. Researchers utilize these proteins to dissect OASL's structural domains, antiviral pathways, and interactions with viral components or host proteins. In therapeutic contexts, recombinant OASL holds potential as an immunomodulatory agent to enhance antiviral responses or as a tool for developing broad-spectrum antiviral strategies. However, its dual roles in promoting inflammation and antiviral activity require careful evaluation for clinical applications. Current studies also explore OASL polymorphisms linked to viral susceptibility, highlighting its relevance in personalized medicine and vaccine design.
×
